MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$816K
Free Cash flow
-$202K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sale of common sto...
Stock-based compensation
Proceeds from sale of exotropin ...
Others
Negative Cash Flow Breakdown
Gain on sale of exotropin intere...
Inventories
Accounts receivable, net of allo...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-04-30
2026-01-31
2025-10-31
2025-07-31
Net loss
-145
-852
-815
-4,706
Depreciation and amortization expense
19
19
20
53
Inducement expense to convert notes
-
-
136
-
Amortization of oid and commitment fee discount promissory notes
2
-16
-
18
Amortization of debt discount promissory notes
-
-
39
-
Stock-based compensation
590
592
756
3,937
Bad debt expense
-
-
0
-
Gain on sale of exotropin interests
-390
-
-
-
Change in obligation to repurchase shares
17
-19
0
2
Accounts receivable, net of allowance for bad debts
214
27
35
-194
Other receivable
-
-
-1
-2
Prepaid expenses
45
134
-212
237
Reserve of non- marketable securities related party
-
-
-
0
Inventories
234
79
165
26
Write-off of advances payable to former officer
-
-
-
0
Accounts payable and accrued expenses
236
-9
-403
603
Security deposits
-11
-
-
0
Deferred revenue
37
36
-111
-175
Net cash used in operating activities
-138
-471
-383
-335
Investment in non-marketable equity securities related party
-
-
-
0
Purchase of fixed assets
64
14
0
23
Proceeds from sale of exotropin interests
376
-
-
-
Net cash provided by financing activities
312
-14
0
-23
Proceeds from sale of common stock
650
1,300
300
0
Proceeds from exercise of warrants
-
-
0
50
Payments on finance leases
8
6
10
35
Net cash provided by (used in) financing activities
642
1,294
290
15
Increase (decrease) in cash
816
809
-93
-343
Cash at beginning of period
1,030
221
657
-
Cash at end of period
1,846
1,030
221
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sale of
common stock
$650K
Proceeds from sale of
exotropin interests
$376K
Net cash provided by
(used in) financing...
$642K
Net cash provided by
financing activities
$312K
Canceled cashflow
$8K
Canceled cashflow
$64K
Increase (decrease) in
cash
$816K
Canceled cashflow
$138K
Payments on finance
leases
$8K
Purchase of fixed assets
$64K
Stock-based compensation
$590K
Accounts payable and
accrued expenses
$236K
Deferred revenue
$37K
Depreciation and
amortization expense
$19K
Change in obligation to
repurchase shares
$17K
Amortization of oid and
commitment fee discount ...
$2K
Net cash used in
operating activities
-$138K
Canceled cashflow
$901K
Gain on sale of
exotropin interests
-$390K
Inventories
$234K
Accounts receivable, net
of allowance for...
$214K
Net loss
-$145K
Prepaid expenses
$45K
Security deposits
-$11K
Buy us a coffee
Zeo ScientifiX, Inc. (ZEOX)
Zeo ScientifiX, Inc. (ZEOX)